Cutaneous CD56+ T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma

Yixuan James Zheng, Albert Lee, Laura Pincus, Wilson Ho, Marin Vujic, Susana Ortiz‐Urda

JAAD Case Reports · 2018 · 16 citations · 6 references

DOIFull text

Open access

Concepts

Abstract

Pembrolizumab is an anti–programmed cell death receptor protein-1 (PD-1) monoclonal antibody first approved in 2014 by the US Food and Drug Administration for the treatment of metastatic melanoma. Pembrolizumab targets the PD-1, blocking the immune checkpoint and subsequently boosting the immune response against cancerous cells. Although effective against systemic disease, anti–PD-1 therapy is also associated with adverse effects such as vitiligo and pruritus caused by overstimulation and hyperproliferation of the immune system.

References

6